AstraZeneca gains global rights to Rigel's preclinical JAK inhibitor aimed at asthma
This article was originally published in Scrip
Executive Summary
AstraZeneca has entered into an agreement with Rigel Pharmaceuticals for the development and commercialisation of Rigel's preclinical inhaled JAK inhibitor, R256, shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma.